Over the last decade, a lot of publications established a link between gut microbiota composition and patients’ outcome after hematopoietic stem cell transplantation. In particular, a large retrospective multi-center study demonstrated that gut microbiota diversity after or during recovery but also before the start of the conditioning regimen was associated with a decreased overall survival after hematopoietic cell transplantation...
Over the last decade, a lot of publications established a link between gut microbiota composition and patients’ outcome after hematopoietic stem cell transplantation. In particular, a large retrospective multi-center study demonstrated that gut microbiota diversity after or during recovery but also before the start of the conditioning regimen was associated with a decreased overall survival after hematopoietic cell transplantation.
Based on these very important results, this suggests that gut microbiota modulation before and after transplantation will be important to improve microbiota diversity recovery and improve patient outcomes. So, in the future, I really think that we will have these gut microbiota modulation based in particular on fecal microbiota transplantation but maybe also more precisely designed treatments based on a consortium of bacteria to improve this microbial diversity. We also think that we will have a new algorithm regarding the use of prophylactic or therapeutic antibiotics to decrease the impact of gut bacteria diversity and improve the patient’s outcome.
Regarding today, we already have the strongest base of fecal matter transplantation for the treatment of steroid-resistant acute graft-versus-host disease with several studies that have been reported and also a very important study that is presented during the EBMT this year that’s included a large number of patients treated within the clinical trial. 24 patients but also [inaudible] access program that treated 52 patients as a treatment of steroid-resistant acute graft-versus-host disease so this is that demonstrates that FMT was safe and effective with a high response rate and now we expect that this treatment will be used in steroid-resistant and ruxolitinib-resistant acute graft-versus-host disease.
